V The Indian biotech industry has grown 3-fold in just 5 years to

report revenues of US $3 billion in 2009-10.

V South continues to remain India¶s largest Biotech cluster - 9

new biotech companies.

V The region has 172 biotech companies which posted revenues

of Rs55.37bn during the year making up 39% of the overall
revenues.

V Mumbai outpaced Bangalore, with a small margin of about

Rs2bn, to become India¶s Top Biotech City in terms of
revenue.
V The Biopharma sector contributed nearly three-fifth to
industry¶s revenues at Rs.88.29bn a growth of 12%

V Bioservices at Rs.26.39bn and Bioagri at Rs.19.36bn.

V Bioindustrials segment with a contribution of Rs.5.64bn.

V Bioinformatics at Rs.2.31bn.

V Biopharma and Bioservices sector contributed 63% and 33% to

the total biotech exports respectively.

V The Bioagriculture, Bioindustrial and Bioinformatics Sectors

remained focused on domestic operations bringing in nearly
90% of their revenues from India.
V Companies in western India - 46 percent of the total biotech
market at Rs.6,631 crore.

V Southern India made up for 39 percent of the overall revenues

at Rs.5,537 crore

V Northern bio-cluster contributed just a seventh of the revenues

at Rs.2,030 crore.

V Eastern India did not add any significant revenue to the

country's overall biotech revenue.
V Bangalore-based Biocon regained its top slot with earnings at
Rs.11.8 billion.

V Second - Pune's Serum Institute of India at Rs.8.5 billion.

V Third top grosser was Panacea Biotec at Rs.7 billion.

V Hyderabad based Nuziveedu Seeds Limited (NSL) sold nearly 7

million packets of Bt cotton seeds in 2009-10 giving it a market
share of 36%

V Cautious optimism within the biotech industry - recent government

efforts.

V Industry is maturing and its annual growth will be around 20 percent

in the near future.
£
 
 
    



V The Indian advantage ² high quality scientific talent pool, lower

operational costs, development speed and access to a large market;
based on co-development.

V Bristol-Myers Squibb¶s collaboration with Biocon.

V Partnerships now range from discovery to early clinical development

- significant upsides even for the partnering firms.

V Drug maker AstraZeneca - currently altering its R&D strategy by

slimming down operations in the US and Europe and reinvesting it in
Asia across India, China and Japan.

V It recently partnered with Torrent and has signed a research

collaboration with Jubilant Biosys.
V Cipla to market the biosimilars ± Roche & Amgen, in India and
overseas under an agreement with Shanghai-based partner
Desano Pharma

V Cipla to invest US$65mn over three years buying 40% of a

company based in Goa and a 25% stake in a Hong Kong-based
biotechnology company

V Reliance Life Sciences ± to revive its plans to set up a large

integrated pharmaceutical company with generic focus - in a
phased manner, with investments in new plants and facilities
over the years.

V Reliance - global pharma business ² oncology, peptides,

steroids and hormones; has already launched four cancer drugs
in the Indian market.
V Ranbaxy may close down unit in Mohali - To outsource either
products or manufacturing capacities for its business, but in
countries which are outside its top 20 markets. 6
 











V According to reports, Parabolic Drugs has bagged a contract to

make two key bulk drugs for Ranbaxy, without naming the
products.

V Patent Expiry May Open $90 Billion Drug Market for Dr.
Reddy¶s - biggest beneficiary among Indian generic-drug makers
as $157 billion of medicines including Eli Lilly & Co.¶s Zyprexa
lose patent protection within five years.

V 73 applications awaiting approval - will be able to supply generic

versions of medications that generated about $90 billion in U.S.
sales in 2008.
V Patents
for at least 91 drugs, with combined annual
revenue of $157 billion in 2008, will expire from
2010 to 2015, according to a report from HDFC.

V These include Merck & Co.¶s top-selling Singulair for

treating asthma and Pfizer Inc.¶s Lipitor cholesterol
pill.

V U.S.revenue at Indian pharmaceutical companies will

rise more than 20 percent annually over the next five
years, helped by drug patent expiries and greater use
of generics, according to India Infoline Ltd.
V Sun Pharma gets USFDA nod to market
generic version of Pfizer's Xanax alprazolam
tablets. 6
 

 



 




V Annual sale in US of branded and generic

alprazolam tablets is estimated at US$145mn.

V Mudra Connext, a unit of Mudra MAX

(Integrated Communications Planning &
Implementation) has bagged the media
mandate for Apollo Hospitals.